Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile.
Alexandra IkeguchiMichael MachiorlattiSara K VeselyPublished in: Melanoma management (2020)
Analysis of this large database of unselected node-positive melanoma patients demonstrated a positive survival benefit of immunotherapy across all demographic factors assessed and the impact was greater for patients 65 years of age and older.